New share news | Qi Yunshan Food (02797) listing has ended, with subscription reaching HK$14.3 billion, oversubscribed by 714 times.
Qiyunshan Food (02797) was listed for subscription from June 30, 2026 to July 6, 2026, and the subscription has now ended.
Fruit Snack Company Qiyunshan Food (02797) conducted its IPO from June 30, 2026 to July 6, 2026, and the IPO has now ended. According to market reports, Qiyunshan Food received a margin loan of HK$14.305 billion from brokers, with a public offering size of HK$0.2 billion, oversubscribed 714.26 times.
The IPO plan stated that the company planned to globally offer 25 million H shares, with 10% for public offering in Hong Kong and 90% for international offering. The selling price per share is between HK$5 and HK$8. Each lot consists of 500 H shares, and it is expected that H shares will commence trading on the Hong Kong Stock Exchange on the morning of July 9, 2026 (Thursday).
According to the prospectus, Qiyunshan Food is a fruit snack company in China that mainly sells products made from jujubes. The group's brand, "Qiyunshan," is a well-known jujube product brand in China. The group is positioned as a green food company, utilizing the natural health benefits of jujubes to meet consumers' diverse taste preferences through research and development, and is committed to promoting the value of jujubes as a nutritious snack.
According to data from Insight Consulting, the group held a 29.0% share in the Chinese market for jujube products by retail sales in 2025, ranking first in the industry. Since 1997, the group's flagship product, jujube cakes, has been certified as "green food" by the China Green Food Development Center for 30 consecutive years and was awarded the "National Geographical Indication Protection Product" certification in 2018.
The company established the Jiangxi Jujube Engineering and Technology Research Center in 2014. The group's operations cover the entire industry chain from jujube food resource protection, cultivation, food research and development, manufacturing, to sales. The group has been recognized as a high-tech enterprise and a key national leading agricultural industrialization enterprise.
In terms of finances, during the previous periods, Qiyunshan's gross profit for the fiscal years 2023, 2024, and 2025 was RMB 120 million, RMB 165 million, and RMB 161 million respectively, with gross profit margins of 48.8%, 48.6%, and 51.3% for the same years. The group's net profit for the fiscal years 2023, 2024, and 2025 was RMB 23.7 million, RMB 53.2 million, and RMB 48.9 million respectively.
Related Articles
.png)
CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.

US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.

GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.
CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.
.png)
US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.

GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.

RECOMMEND





